MX391944B - Estatinas de dosis altas para degeneración macular relacionada con la edad. - Google Patents

Estatinas de dosis altas para degeneración macular relacionada con la edad.

Info

Publication number
MX391944B
MX391944B MX2018004636A MX2018004636A MX391944B MX 391944 B MX391944 B MX 391944B MX 2018004636 A MX2018004636 A MX 2018004636A MX 2018004636 A MX2018004636 A MX 2018004636A MX 391944 B MX391944 B MX 391944B
Authority
MX
Mexico
Prior art keywords
age
macular degeneration
related macular
amd
prevent
Prior art date
Application number
MX2018004636A
Other languages
English (en)
Other versions
MX2018004636A (es
Inventor
Demetrios Vavvas
Joan W Miller
Original Assignee
Massachusetts Eye & Ear Infirmary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye & Ear Infirmary filed Critical Massachusetts Eye & Ear Infirmary
Publication of MX2018004636A publication Critical patent/MX2018004636A/es
Publication of MX391944B publication Critical patent/MX391944B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los métodos de uso de una estatina de dosis alta para el tratamiento de AMD en un paciente se pueden usar para causar una regresión de las drusas y/o desprendimientos epiteliales del pigmento drusenoide (PEDs), para prevenir atrofia del RPE y/o uno o más fotorreceptores, para prevenir la pérdida de visión y/o mejorar la agudeza visual, y/o para prevenir la progresión de AMD seca a AMD húmeda.
MX2018004636A 2015-10-14 2016-10-14 Estatinas de dosis altas para degeneración macular relacionada con la edad. MX391944B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562241522P 2015-10-14 2015-10-14
PCT/US2016/056987 WO2017066529A1 (en) 2015-10-14 2016-10-14 High-dose statins for age-related macular degeneration

Publications (2)

Publication Number Publication Date
MX2018004636A MX2018004636A (es) 2019-06-20
MX391944B true MX391944B (es) 2025-03-21

Family

ID=58517927

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004636A MX391944B (es) 2015-10-14 2016-10-14 Estatinas de dosis altas para degeneración macular relacionada con la edad.

Country Status (13)

Country Link
US (2) US11331295B2 (es)
EP (1) EP3362063B1 (es)
JP (3) JP7037186B2 (es)
AU (1) AU2016338540B2 (es)
CA (1) CA3001661C (es)
DK (1) DK3362063T3 (es)
ES (1) ES2941347T3 (es)
FI (1) FI3362063T3 (es)
IL (1) IL258604B2 (es)
MX (1) MX391944B (es)
PH (1) PH12018500745B1 (es)
WO (1) WO2017066529A1 (es)
ZA (1) ZA201803097B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208970A1 (en) * 2017-05-09 2018-11-15 Massachusetts Eye And Ear Infirmary Biomarkers for age-related macular degeneration
WO2019018350A1 (en) * 2017-07-17 2019-01-24 Keith Roizman TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES
EP3697285A4 (en) * 2017-10-17 2021-06-30 Apeliotus Technologies, Inc. FUNCTIONAL BIOMARKERS FOR STATIN THERAPY IN AGE-RELATED MACULAR DEGENERATION (AMD)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030065020A1 (en) * 2001-07-13 2003-04-03 Catharine Gale Treatment of macular degeneration
JP2005525368A (ja) 2002-03-04 2005-08-25 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストをＨＭＧ−ＣｏＡ還元酵素阻害剤またはビスフォスフォネートと併用投与する障害の予防または治療方法
US20050250745A1 (en) * 2004-02-25 2005-11-10 Seddon Johanna M Biomarkers for age-related macular degeneration (AMD)
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CA2593846A1 (en) * 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
US20100034749A1 (en) 2006-07-10 2010-02-11 Medigene Ag Use of a Cationic Collodal Preparation for the Diagnosis and Treatment of Ocular Diseases
JP2008268506A (ja) * 2007-04-19 2008-11-06 Fuji Xerox Co Ltd 現像装置、像保持体ユニットおよび画像形成装置
WO2009023411A1 (en) 2007-08-09 2009-02-19 Bausch & Lomb Incorporated Compositions and methods for treating or controlling anterior- and posterior-segment ophthalmic diseases
US20120156202A1 (en) 2010-11-05 2012-06-21 Shantha Totada R Age related macular degeneration treatment
JP2016530295A (ja) 2013-09-06 2016-09-29 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｃｙｒ６１及びｖｅｇｆ媒介性の状態の治療
WO2016009430A1 (en) 2014-07-14 2016-01-21 Yeda Research And Development Co. Ltd Reduction of aging-induced type i interferon signaling at the brain's choroid plexus or within the cns for treatment of disease or injury of the cns
WO2016018665A1 (en) 2014-07-31 2016-02-04 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol

Also Published As

Publication number Publication date
FI3362063T3 (fi) 2023-04-06
CA3001661C (en) 2025-05-06
DK3362063T3 (da) 2023-04-03
MX2018004636A (es) 2019-06-20
IL258604B2 (en) 2024-09-01
EP3362063A1 (en) 2018-08-22
IL258604B1 (en) 2024-05-01
EP3362063B1 (en) 2023-01-11
JP7037186B2 (ja) 2022-03-16
JP2024016045A (ja) 2024-02-06
AU2016338540A1 (en) 2018-05-24
NZ742203A (en) 2025-06-27
JP2022003042A (ja) 2022-01-11
PH12018500745B1 (en) 2023-03-15
ZA201803097B (en) 2022-12-21
IL258604A (en) 2018-06-28
AU2016338540B2 (en) 2022-04-28
JP2018530586A (ja) 2018-10-18
US20190209522A1 (en) 2019-07-11
CA3001661A1 (en) 2017-04-20
US20210077457A1 (en) 2021-03-18
US11331295B2 (en) 2022-05-17
PH12018500745A1 (en) 2018-10-15
ES2941347T3 (es) 2023-05-22
US11744817B2 (en) 2023-09-05
EP3362063A4 (en) 2019-06-19
JP7754480B2 (ja) 2025-10-15
WO2017066529A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
CY1123622T1 (el) Τροποποιημενα μηνιγγιτιδοκοκκικα fhbp πολυπεπτιδια
CY1120893T1 (el) Μεθοδοι για αγωγη μολυνσεων ιου filoviridae
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
MX2018014869A (es) Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
DK3399962T3 (da) Oftalmisk sammensætning til behandling af tør øjensygdom
MX2018010292A (es) Tratamiento de condiciones oculares alergicas con ciclodextrinas.
CL2016002815A1 (es) Solución oftálmica acuosa y método para tratar el síndrome del ojo seco
EP3556858A3 (en) Crispr/cas-related methods and compositions for treating cystic fibrosis
MX373692B (es) Composiciones y metodos para la mejora de la vision a distancia y el tratamiento de errores de refraccion del ojo.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
MX393900B (es) Uso de gaboxadol en el tratamiento de tinnitus.
NZ746468A (en) Methods of treating ocular conditions
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
GB201621904D0 (en) Ophthalmic composition for the treatment of ocular infection
EA202091385A3 (ru) Лиофилизированные составы для антидота фактора ха
MX391944B (es) Estatinas de dosis altas para degeneración macular relacionada con la edad.
BR112018009745A8 (pt) compostos heterocíclicos para o tratamento de doença
CY1122457T1 (el) Μη πτητικες οφθαλμικες συνθεσεις, ειδικες για τη θεραπεια της ξηροφθαλμιας
LT3541335T (lt) Sausų akių gydymo kaukė
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet